PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
752.87%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
752.87%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
22.99%
Interest expense growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Operating income decline while TRVN shows 14.24% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
675.86%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
-675.86%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2175.00%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-2175.00%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
-66.67%
Share count reduction while TRVN shows 0.01% change. Joel Greenblatt would examine strategy.
-66.67%
Diluted share reduction while TRVN shows 0.01% change. Joel Greenblatt would examine strategy.